Related Experiment Videos
Iodine-125 interstitial implants as salvage therapy for recurrent gynecologic malignancies
S K Sharma1, H Forgione, J H Isaacs
1Department of Obstetrics and Gynecology, Loyola University Medical Center, Maywood, IL 60153.
Cancer
|May 15, 1991
Summary
Iodine-125 interstitial implants effectively treated recurrent gynecologic pelvic malignancies, achieving high response rates and complete local control in most patients. This study details survival, response, and complications for this advanced cancer treatment.
Area of Science:
- Oncology
- Radiology
- Gynecology
Background:
- Recurrent gynecologic pelvic malignancy presents a significant clinical challenge.
- Previous treatments like surgery and radiation therapy have limitations in managing these advanced cases.
Purpose of the Study:
- To evaluate the efficacy and safety of iodine-125 (I-125) interstitial implants for recurrent gynecologic pelvic malignancies.
- To analyze the overall survival time, volume-response relationship, and complications associated with I-125 brachytherapy.
- To present the radioresponse of various histologic types in recurrent pelvic cancers.
Main Methods:
- Twenty-one patients with recurrent gynecologic pelvic malignancy were treated with iodine-125 (I-125) interstitial implants.
- A retrospective analysis was conducted on patient outcomes, including response rates, survival, and complications.
- Histologic types of the malignancies were analyzed for differential radioresponse.
Main Results:
- Ninety percent of patients with prior treatment (surgery and radiation) showed a response to I-125 implants.
- Seventy-five percent of patients achieved a complete local response.
- The study discusses overall survival, volume-response relationships, and complications, alongside the radioresponse of different histologic subtypes.
Conclusions:
- Iodine-125 interstitial implants demonstrate significant efficacy in treating recurrent gynecologic pelvic malignancies.
- High rates of complete local response and overall survival can be achieved with I-125 brachytherapy.
- Further investigation into the volume-response relationship and histologic variations is warranted.